Parallel Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History
Parallel Advisors, LLC
- $4.34 Billion
- Q4 2024
A detailed history of Parallel Advisors, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 737 shares of APLS stock, worth $17,886. This represents 0.0% of its overall portfolio holdings.
Number of Shares
737
Previous 1,879
60.78%
Holding current value
$17,886
Previous $54,000
57.41%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding APLS
# of Institutions
300Shares Held
111MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$297 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$289 Million17.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$244 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$234 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$141 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.67B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...